# Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

> **NCT05833867** · PHASE1 · RECRUITING · sponsor: **Shilpa Gupta, MD** · enrollment: 20 (estimated)

## Conditions studied

- Localized Muscle Invasive Bladder Urothelial Carcinoma
- Muscle-Invasive Bladder Carcinoma

## Interventions

- **DRUG:** Sacituzumab govitecan
- **RADIATION:** Adaptive Radiotherapy

## Key facts

- **NCT ID:** NCT05833867
- **Lead sponsor:** Shilpa Gupta, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-06
- **Final completion:** 2027-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833867, "Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05833867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*